All News

cardiac2.jpg (keep)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

d Jack Cush, MD

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.

Read Article
pills.bottle.hand__0.jpg

EULAR Guidance on Patient Adherence to Meds

d Jack Cush, MD

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force

Read Article
backpain.hip_.jpg (keep)

Spinal Benefits Seen With Cosentyx in PsA

d MedPage Today

Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported.

Read Article
New download available! H2H comparison chart. https://t.co/w7tQYXn0us

Links:

Dr. John Cush RheumNow ( View Tweet)

Spinal Benefits Seen With Cosentyx in PsA---Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported. https://t.co/OfkQtAO9Gh https://t.co/hs3NaBjLuF

Links:

Dr. John Cush RheumNow ( View Tweet)
BASE: a controlled, ph 4 safety RCT of IV Belimumab (10 mg/kg) or PBO (+standard Rx) given to 4018 SLE pts over 48 wks. Found no increase in all-cause mortality and special AE: w/ very low event rates (SIE 3·75%, opportunistic infx 1·8%, cancers 0·25%) https://t.co/Zc5BqXQ038

Links:

Dr. John Cush RheumNow ( View Tweet)

44 patient study of sirolimus vs placebo in patients with inclusion body myositis found no difference in the primary outcome of relative knee extension strength, nor in secondary outcomes. SAE were more common w/ sirolimus 45% vs 27% in PBO https://t.co/YhnRTnaGFl

Links:

Dr. John Cush RheumNow ( View Tweet)

2021 Whatever it Takes Let me be blunt. If you’re still waiting for this whole COVID thing to be over with – you’re drifting, going nowhere and you’re setting yourself up for a long hard winter, spring and summer of 2021. Read more on the site. https://t.co/1y172EVpwV https://t.co/W1MAKzOCJS

Links:

Dr. John Cush RheumNow ( View Tweet)
Nice Yale Medicine overview of MIS-C (multisystem inflammatory syndrome in children) due to COVID-19 https://t.co/oYOlJFHzuN

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID-19 Vaccination - Phase Ib Begins The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines. https://t.co/7fGCnHJnvy https://t.co/AiBBW94kR5

Links:

Dr. John Cush RheumNow ( View Tweet)
Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO). AEs unremarkable w/ 1 case of depression https://t.co/zrsVD7N3Z9

Links:

Dr. John Cush RheumNow ( View Tweet)

Hello 2021 and new drug price hikes - on average a 4.2% hike in over 500 drugs (past years saw an avg hike ~5%). Increases include Cosentyx 7%, Humira & Rinvoq 7.4%, Orencia 4.5%, Taltz 5%, Actemra 3%, Benlysta 5%, Xeljanz 4.9% & Cimzia 4%

Dr. John Cush RheumNow ( View Tweet)

WooHoo. Got my 2nd Covid-19 vax shot. Now my B cells are in overdrive against the nasty COVID. Please get yours. ASAP https://t.co/rRj44GpJxl
Dr. John Cush RheumNow ( View Tweet)
Study of 100 pts w/ Granulomatosis with polyangiitis finds 56% had elevated d-dimer levels and that d-dimer are associated with disease activity and inflammation rather than with the risk of venous thromboembolism. 23 had VTE not predicted by d-dimer https://t.co/zIYKXNl0oO

Links:

Dr. John Cush RheumNow ( View Tweet)

Telemedicine Less Utilized in the South and Urban Areas-- an MMWR student from 7/20 shows that urban health centers were more likely to provide virtual visits that those in rural areas. https://t.co/DU9HjGXOHQ https://t.co/eBJJXK2qg9

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this March for RheumNow Live! Sign up via the link below. https://t.co/vJlU0Z3Q3x https://t.co/G1s3F7zKlI

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 2050 Northern Italian arthritis clinic pts; where 1.1-1.4% of population developed COVID-19. Steroid use was independently associated with increased COVID risk (adj OR 1.23 to 3.20). But Rx w/ ts/bDMARDs had reduced risk (adj OR 0.46). https://t.co/cLXdpzda9t

Links:

Dr. John Cush RheumNow ( View Tweet)

Rifampin is safest! 2 RCTs of 6485 latent TB pts compared 9 mos of isoniazid vs 4 mos of rifampicin. RIF had half the adverse events compared to INH; roughly half the rate of rash (1.5% v 2.7%); No grade 3-4 hepatotoxicity w/ RIF, compared 6%) w/ INH https://t.co/6Nz0zeP8ik

Links:

Dr. John Cush RheumNow ( View Tweet)

MIRROR OL study shows that when pegloticase is co-administered with methotrexate, a high rate of response is seen (79% or 11/14 pts), achieved a complete response (sUA < 6 mg/dL) at Month 6. Topline results announced by Horizon. https://t.co/DNIt5zJJp8

Links:

Dr. John Cush RheumNow ( View Tweet)

Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/8IQRHoPqBl https://t.co/5MkvEKcNJg

Links:

Dr. John Cush RheumNow ( View Tweet)
×